STRAHLENTHERAPIE UND ONKOLOGIE is an esteemed journal published by Springer Heidelberg, focusing on critical advancements and research in the fields of Oncology and Radiology. Established in 1986, this journal has carved its niche within the scientific community, ranking in the Q1 category for Radiology, Nuclear Medicine and Imaging, and Q2 for Oncology as of 2023. With an ISSN of 0179-7158 and E-ISSN 1439-099X, it serves as an essential resource for researchers, professionals, and students dedicated to the complexities of cancer treatment and radiation therapy. While the journal operates under a subscription model, its broad international readership values its rigorous peer-review process and comprehensive coverage of pivotal studies. STRAHLENTHERAPIE UND ONKOLOGIE continues to enhance its impact in the domains of oncology and radiology, as evidenced by its commendable Scopus rankings, including a 76th percentile in Radiology and a 65th percentile in Oncology. Its commitment to disseminating innovative research solidifies its role as a cornerstone in the ongoing quest to improve patient care and therapeutic techniques.

Radiation Oncology Journal, published by the Korean Society of Therapeutic Radiology & Oncology, stands at the forefront of cancer treatment research and innovation within the dynamic fields of oncology and radiology. With a focus on disseminating groundbreaking findings and advancements from 2012 to 2024, this journal aims to foster collaboration among researchers, clinicians, and educators dedicated to improving therapeutic techniques and patient outcomes in the context of radiation therapy. Recognized with a prestigious Q2 ranking in both the Oncology and Radiology, Nuclear Medicine and Imaging categories, it ranks 140th out of 333 in its Scopus category for Medicine Radiology and boasts a 58th percentile placement. While operating on a non-open access basis, the journal remains committed to providing valuable insights and updates to professionals in the field from its base in South Korea. As the landscape of cancer treatment evolves, the Radiation Oncology Journal continues to play a vital role in shaping research trends and enhancing the understanding of radiotherapy's role in comprehensive cancer care.

The Japanese Journal of Radiology, published by SPRINGER, serves as a premier platform for disseminating cutting-edge research and clinical advancements in the fields of radiology, nuclear medicine, and imaging. With an ISSN of 1867-1071 and E-ISSN 1867-108X, this journal has established itself as a vital resource for practitioners, researchers, and students alike. Renowned for its high-quality peer-reviewed articles, it currently enjoys a respectable impact factor within the Q2 category of Scopus rankings, placing it in the 69th percentile among 333 journals in its field. The journal has seen consistent convergence of research from 2009 to 2024, further underscoring its commitment to advancing the understanding of radiological practices. Importantly, the journal offers Open Access options to facilitate widespread dissemination of knowledge, ensuring that vital research reaches its audience without barriers. Addressed in Japan, the Japanese Journal of Radiology plays a critical role in enhancing the global discourse on medical imaging, making it an essential resource for anyone engaged in this dynamic field.

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Journal of Medical Imaging and Radiation Oncology, published by WILEY, is a pivotal resource in the fields of oncology and medical imaging. With an impact factor reflective of its commitment to advancing research, the journal has maintained a robust reputation since its inception in 2008 and continues to thrive through 2024. It is indexed with an insightful ranking, with a Q2 classification in Radiology, Nuclear Medicine and Imaging, affirming its importance in these disciplines. This journal not only serves as an open access platform, allowing extensive reach and accessibility, but also fosters a scholarly community dedicated to the innovation of imaging techniques and radiation oncology practices. As a key player in disseminating crucial findings and advancements, it appeals to researchers, clinicians, and students who aim to contribute to the evolving landscape of medical imaging and cancer treatment methodologies. The journal is based in Australia, at 111 River St, Hoboken, NJ, and invites submissions that push the boundaries of current knowledge in this critical area of healthcare.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.